Retroviral transduction of transforming growth factor-β1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions

Laboratory Investigation

Volumn 74, Issue 4, 1996, Pages 747-760

  Timme, Terry L ^a   Yang, Guang ^a   Rogers, Eammon ^a   Kadmon, Dov ^a   Morganstern, Jay P ^c   Park, Sang Hee ^a   Thompson, Timothy C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ARIAD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC G 418; BETA GALACTOSIDASE; COMPLEMENTARY DNA; CYTOKERATIN; DNA; RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL TISSUE; CELL GROWTH; CELL HYPERPLASIA; CELL TYPE; CONTROLLED STUDY; EMBRYO; GENE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOUTHERN BLOTTING;

3T3 CELLS; ANIMALS; BASE SEQUENCE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEURONS; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC HYPERPLASIA; RETROVIRIDAE; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029918126     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, and Derynck R (1992). Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor β1. J Cell Biol 118: 715-726.
2. Arteaga CL, Carty-Dugger T, Moses HL, Burd SD, and Pietenpol JA (1993). Transforming growth factor β1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 4:193-201.
3. Beauchamp RD, Sheng H-M, Bascom CC, Miller DA, Lyons RM, Torre-Amione G, and Moses HL (1992). Phenotypic alterations in fibroblasts and fibrosarcoma cells that overexpress latent transforming growth factor-β1. Endocrinology 130:2476-2486.
4. Bennett BD and Gardner WA (1985). Embryonal hyperplasia of the prostate. Prostate 7:411-417.
5. Brunner AM, Marquardt H, Malacko AR, Lioubin MN, and Purchio AF (1989). Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor β-1 precursor. J Biol Chem 264:1366-13664.
6. Cepko C (1992). Preparation of a specific retrovirus producer cell line. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl K, editors. Current protocols in molecular biology. New York: John Wiley and Sons, 1-12.
7. Chang H-L, Gillett N, Figari I, Lopez AR, Palladino MA, and Derynck R (1993). Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53:4391-4398.
8. Chen C and Okayama H (1987). High-efficiency transformation of mammalian cells by plasmic DNA. Mol Cell Biol 7:2745-2752.
9. Cleary KR, Choi HY, and Ayala AG (1983). Basal cell hyperplasia of the prostate. Am J Clin Pathol 80:850-854.
10. Cui W, Fowles DJ, Cousins FM, Duffie E, Bryson S, Balmain A and Arkhurst RJ (1995). Concerted action of TGF-β1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev 9:945-955.
11. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, and Foster BA (1992). Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal- epithelial interactions, and growth factors. J Androl 13:465-475.
12. Derynck R, Jarrett JA, Chen EY, and Goeddel DV (1986). The murine transforming growth factor-β precursor. J Biol Chem 261:4377-4379.
13. Devaraj LT and Bostwick DG (1993). Atypical basal cell hyperplasia of the prostate. Am J Surg Pathol 17:645-659.
14. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, and Thompson TC (1995). Transforming growth factor-β1: Comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 5:628-635.
15. Egawa S, Kadmon D, Miller GJ, Scardino PT and Thompson TC (1992). Alterations in mRNA levels for growth related genes following transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma. Mol Carcinog 5:52-61.
16. Einheber S, Hannocks M-J, Metz CN, Rifkin DB, and Salzer JL (1995). Transforming growth factor-β1 regulates axon/schwann cell interactions. J Cell Biol 129:443-458.
17. Flanders KC, Thompson NL, Cissel DS, Obberghen-Schilling EV, Baker CC, Kass ME, Ellingsworth LR, Roberts AB, and Sporn MB (1989). Transforming growth factor-β1: Histochemical localization with antibodies to different epitopes. J Cell Biol 108:653-660.
18. Jhappan C, Geiser AG, Kordaon EC, Bagheri D, Hennighausen L, Roberts AB, Smith GH, and Merlino G (1993). Targeting of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 12:1835-1845.
19. Kulkarni AB, Huh G-G, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, and Karlsson S (1993). Transforming growth factor β1 null mutation in mice causes excessive inflamatory response and early death. Proc Natl Acad Sci USA 90:770-774.
20. Markowitz D, Goff S, and Bank A (1988). A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J Virol 62:1120-1124.
21. Massague J (1990). The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641.
22. McNeil J (1978). Origin an evolution of benign prostatic enlargement. Invest Urol 16:340-345.
23. Merz VW, Miller GJ, Krebs TK, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, and Thompson TC (1991). Elevated transforming growth factor-β1 and β3 mRNA levels are associated with ras+myc-induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Mol Endocrinol 5:503-513.
24. Morganstern J and Land H (1990). Advanced mammalian gene transfer: High titer retroviral vectors with multiple drug selection markers and a complementatary helper-free packaging cell line. Nucleic Acids Res 18:3587-3596.
25. Pierce DF, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BLM, and Moses HL (1993). Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Dev 7:2308-2317
26. Prehn JHM, Peruche B, Unsicker K, and Krieglstein J (1993). Isoform-specific effects of transforming growth factors-β on degenergation of primary neuronal cultures induced by cytotoxic hypoxia or glutamate. J Neurochem 60:1665-1672.
27. Price J, Turner D, and Cepko CL (1987). Lineage analysis in the vertebrate nervous system by retrovirus mediated gene transfer. Proc Natl Acad Sci USA 84:156-160.
28. Roberts AB and Sporn MB (1990). The transforming growth factor-betas. In: Sporn MB and Roberts AB, editors. Peptide growth factors and their receptors. Berlin: Springer-Verlag, 419-472.
29. Rogister B, Detrée P, Leprince P, Martin D, Sadzot C, Malgrange B, Munaut C, Rigo JM, Lefebvre PP, Octave J-N, Schoenen J, and Moongen G (1993). Transforming growth factor β as a neuronoglial signal during peripheral nervous system response to injury. J Neurosci Res 34:32-43.
30. Roop DR, Cheng CK, Toftgard R, Stanley JR, Steinert PM, and Yuspa SH (1985). The use of cDNA clones and monospecific antibodies as probes to monitor keratin gene expression. Ann N Y Acad Sci 455:426-435.
31. Sellheyer K, Bickenbach JR, Rothnagel JA, Bundman D, Longley MA, Krieg T, Roche NS, Roberts AB, and Roop DR (1993). Inhibition of skin development by overexpression of transforming growth factor β1 in the epidermis of transgenic mice. Proc Natl Acad Sci USA 90:5237-5241.
32. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, and Doetschman T (1992). Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693-699.
33. Southern P and Berg P (1982). Transformation of cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1:327-341.
34. Sporn MB and Roberts AB (1992). Transforming growth factor-β: Recent progress and new challenges. J Cell Biol 119:1017-1021.
35. Steiner MS and Barrack ER (1992). Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25.
36. Story MT, Hopp KA, Meier DA, Begun FP, and Lawson RK (1993). Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 22:183-197.
37. Story MT, Sasse J, Jacobs SC, and Lawson RK (1987). Prostatic growth factor: Purification and structural relationship to basic fibroblast growth factor. Biochemistry 26:3843-3849.
38. Thompson TC, Southgate J, Kitchner G, and Land H (1989). Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917-930.
39. Thompson TC, Timme TL, Kadmon D, Park SH, Egawa S, and Yoshida I (1993). Genetic predispoition and mesencyhymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 7:165-179.
40. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, Park SH, and Thompson TC (1994). Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 134:1039-1045.
41. Torre-Aminone G, Beauchamp R D, Koeppen H, Park BH, Schreiber H, Moses HL, and Rowley DA (1990). A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490.
42. Truong LD Kadmon D, McCune BK, Flanders KC, Scardino PT, and Thompson TC (1993). Association of transforming growth factor-β1 with prostate cancer: An immunohistochemical study. Hum Pathol 24:4-9.
43. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, and McKeehan WL (1992). Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 6:2123-2128.